In patients with B-cell malignancies, clinical trials of chimeric antigen receptor (CAR) T cells have begun to report remarkable response rates and long-lasting remissions. However, for patients who lack enough T cells to generate CAR T cells or cannot withstand the treatment for the time required to generate CAR T cells, this promising treatment method is out of reach.
To avoid these obstacles, researchers are turning to natural killer (NK) cells to expand the application of CAR-directed therapy in patients with B-cell malignancies. As the leading cell therapeutics provider, Creative Biolabs supplies high-quality CellRapeutics™ CAR-NK vector construction service tailored to your special needs.
The beauty of NK cells is that they can provide patients with allogeneic NK cells, which do not cause GVHD like allogeneic T cells. This simple beauty may translate into potentially huge benefits of CAR-oriented therapy. NK cells from cord blood can be engineered to express CAR and then stored for use in almost all patients. This approach not only eliminates the need to create a new batch of tumor-targeted cells for each patient but also eliminates waiting times that can last for several weeks.
In addition to providing CAR vector design and construction services, we also provide NK cells collected from cord blood samples for CAR-NK targeted therapy. The CAR retroviral vector provided by us further supports stable transduction to modify cells to introduce several new genes with specific functions into the DNA of NK cells.
In general, Creative biolabs provides four generations of CAR products. The first-generation CAR composed of basic elements has been widely used in clinical trials of early cancer immunotherapy. Unlike the first generation with an intracellular signaling domain (such as CD3ζ or FcεRIγ), our second-generation CAR consists of an activation domain and a costimulatory signaling domain (such as CD28 or 4-1BB), whose structure can support longer Time anti-tumor effect. Similar to this strategy, two different costimulatory signal regions were constructed in the third-generation CAR to promote T cell activation signals and significantly enhance CAR-T cell proliferation and survival. In addition, the fourth-generation CAR construct has been engineered with inducible expression units (such as cytokines (such as IL-12)). This inducible transgenic cytokine gene can effectively overcome the "target, off-tumor" defect.
Fig.1 CAR design evolution.
In addition to designing and cloning the conventional scFv-based CAR generations, we also provide multiple novel CAR vector products, such as TanCAR，Universal CAR, VHH-based CAR, and Switch CAR, etc. You can explore more special CARs at CAR Design & Construction to find the product you are interested in. Don't hesitate to contact us to find a customized solution that suits your needs.
Creative Biolabs can also provide CAR-modified NK cells for different cancer research purposes. We provide multiple NK cell lines from various sources, such as cord blood, bone marrow, human embryonic stem cells, donor-derived, and induced pluripotent stem cells. Please refer to the Immune Cell Products to choose the right cells for your research. Moreover, our CAR engineered-NK cells are validated to express CARs with high activity against cancer cells.
With state-of-art CAR development platforms and advanced technologies, Creative Biolabs is capable of offering one-stop CAR-NK cell development services. Please contact us for more details.
All services and products are only for lab research use, not for any clinical diagnosis or treatment.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE